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Abstract The purpose of this study was to evaluate if an early
exposure to human papillomavirus (HPV) during the prenatal
period or infancy could result in HPV16-specific T helper
(Th) responses resembling those of adults with HPV-induced
lesions. We tested HPV16-specific cell-mediated immunity
(CMI) in children born with HPV-positive umbilical cord
blood and/or placenta or having persistent oral HPV infection
and in constantly oral HPV-negative controls. Peripheral
blood mononuclear cells from 33 children from the Finnish
HPV Family Study cohort (mean age 14.7 years) were stimu-
lated with peptide pools covering the amino acid sequence of
the HPV16 E2, E6, and E7 proteins. Lymphocyte prolifera-
tion, secretion of cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-5,
IL-10, IL-17A), and the frequency of Foxp3+ regulatory T-
cells were determined in relation to the HPV DNA status
during a 14-year follow-up. 73.6% of cases and 85.7% of
controls responded against HPV16 E2, while reactivity
against E6 was found in 10.5 and 35.7%, respectively. The
proliferative response against E6 and E7 was more frequent in
controls than in cases (p = 0.047). No HPV16-specific CMI
response or antibodies were detected in two children with
persistent oral HPV16. The profiles of induced cytokines in-
dicated higher levels of IL-5, IL-10, and IL-17A in children
with HPV DNA in placenta and/or cord blood than in other
children. HPV16-specific CMI is common in HPV DNA-
negative children. The cytokine profile in children infected
with HPV16 during early life suggests that the viral dose
and/or specific environment created by the placenta may have
significant impact on the type of HPV-specific immunity.
Introduction
Human papillomavirus (HPV) infection is generally regarded
as a sexually transmitted disease. However, several studies,
including those of our own [14, 18, 22, 31], have shown that
HPV can be detected in the oral mucosa of newborn babies
and young, sexually inexperienced children, suggesting that
alternative, non-sexual routes for HPV infection are plausible.
We have shown a strong concordance between the HPV
genotypes detected in the mother’s genital tract and her off-
spring’s oral samples [14], implying that the HPV-infected
mother is the most probable source of HPV infection of the
newborn. This view is also supported by others [8, 10, 16, 20,
24] reporting vertical transmission rates between 18.2 and
53.3% in the mother–baby pairs. In line with this, we reported
highly concordant serum antibody profiles for HPV-L1 anti-
gens in the mother–baby pairs [14].
Vertical transmission of HPV from a mother to her infant is
still under debate, and several possible modes have been im-
plicated: during (i) fertilization, (ii) pregnancy (prenatal), or
(iii) delivery (perinatal). We recently provided evidence for
prenatal transmission, as we found that the presence of HPV
in placenta and/or in cord blood increased the risk of the new-
born to carry HPV DNA in the oral mucosa [odds ratio
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(OR) = 14.0; 95% confidence interval (CI), 3.7–52.2; p =
0.0001 and OR = 4.7; 95% CI, 1.4–15.9; p = 0.015, respec-
tively) [14, 25]. This implicates that the placenta may play
an important role in the transmission of HPV, not unlike sev-
eral other human viruses [42]. Indeed, studies on the role of
the placenta and other maternal microbiomes as regulators of
neonates’ microbiomes have increased only recently [28],
attesting the view that the fetus can be exposed to microbiota
during pregnancy, with long-term sequels in their health.
Thus, the placenta has been suggested to act as a site where
the translocated maternal oral microbes are presented to the
fetal immune system, resulting in the development of prenatal
tolerance to the maternal microbiome [43].
The significance of early encounters with HPV in the pre-
or perinatal period is unclear. Because of the immaturity of the
immune system of the fetus and infant [7], any early exposure
to HPV might possess a major impact in the development of
HPV-specific immunity, subsequent HPV infections, and their
eventual progression. However, HPV-specific immunity in
children has remained a practically uncharted area. Prompted
by the observations of HPV infections among children, we
decided to study HPV-specific immunity during childhood.
Unexpectedly, many children aged 12–14 years had
HPV16 E2-, E6-, and E7-specific immunoreactivity [13, 15].
Previous studies have reported much lower frequency of
HPV16-specific cell-mediated immunity (CMI) in adults [3,
4, 34, 35, 37, 38, 40, 41]. In adults, differences in the memory
T helper (Th) cell reactivity against HPV16 E2, E6, and E7
oncoproteins have been found between HPV-positive and
HPV-negative subjects. In healthy individuals, the Th respon-
siveness against HPV16 E2 and E6 seems to bemore common
and accompanied by the secretion of both type 1 and type 2
cytokines in a mixed pattern than in subjects with HPV16-
induced disease.
Given the previously shown close association between
HPV DNA in the placenta and/or cord blood and oral HPV
carriage of the child, we hypothesized that those children ex-
posed to HPV via placenta or cord blood and/or with persis-
tent oral HPV might present HPV16-specific Th responses
resembling those of adults with HPV-induced lesions, highly
divergent from constantly HPV-negative controls. We, there-
fore, studied the HPV16 E2-, E6-, and E7-specific immune
response and surveyed other characteristics, including verti-




The current study is part of the Finnish HPV Family Study,
which is a longitudinal cohort study conducted at the
Department of Oral Pathology, Institute of Dentistry,
University of Turku and the Department of Obstetrics and
Gynecology, Turku University Central Hospital. Originally,
329 pregnant women in their third trimester of pregnancy
and all their newborns were enrolled in the study between
1998 and 2001, as described previously [15, 22, 23]. The
newborns were actively followed up for 6 years (mean
54.9months, median 62.4 months). Of these children, 33 were
selected according to the follow-up data: 16 children, who had
either HPV DNA detected in umbilical cord blood and/or
placenta and/or HPV DNA detected in oral mucosa continu-
ously (>24 months), and 17 children, who stayed constantly
HPV-negative during the follow-up. Of these children, 26
were recalled personally to give blood samples for CMI anal-
yses and oral scrapings for HPV testing. Seven of the selected
33 children had been tested previously [13, 15]. A written
informed consent was obtained from all these children and
their parent(s). In total, 11 of 18 girls had received prophylac-
tic bivalent HPV vaccination (Cervarix) before the sample
collection, whereas none of the 15 boys had. In addition to
the samples collected during the present study, we also had
access to all previous follow-up data on these children.
The authors acknowledge the concept of the Minimal
Information About T cell Assays (MIATA) framework [2, 12].
HPV DNA detection and HPV antibody screening
Oral scrapings from the children were taken from the buccal
mucosa of both cheeks and superior and interior vestibule
using a cytobrush (Medscand) [22] at birth, at the age of
3 days, at 1, 2, 6, 12, 24, 36, and 72 months, and at the last
time point, which was, on average, 14.7 years. DNA was
extracted from scraping samples using the high salt method
[19, 30]. First, the high-risk HPV types were detected by
nested polymerase chain reaction (PCR) with MY09/MY11
and GP05+/GP06+ primers. HPV genotyping was done with
the Multimetrix® assay (Multimetrix, Regensburg,
Germany), as described earlier [32], which detects the follow-
ing low-risk (LR) HPV types: 6, 11, 42, 43, 44, and 70 and
high-risk (HR) HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 73, and 82. The median fluores-
cence intensity (MFI) of at least 100 beads was computed for
each bead set in the sample. The cut-off value for each HPV
probe individually was defined by 1.5 ×MFI + 15MFI. Blood
samples for the detection of HPV-specific serum antibodies
were collected from children at the age of 1, 2, 6, 12, 24, and
36 months and sent for analysis to the German Cancer
Research Center (DKFZ), Heidelberg, Germany. Serum anti-
bodies for the major capsid protein L1 of HPV types 6, 11, 16,
18, and 45 were analyzed by multiplex HPV serology, based
on glutathione S-transferase fusion-protein capture on fluores-
cent beads [36]. The results were analyzed and compared with
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each other by using two different cut-off levels (i.e., 200 MFI
and 400 MFI) [32].
Blood samples for CMI studies
Venous blood samples (54 mL) were collected in sodium-
heparin collection tubes from children at the indicated time
points and the peripheral mononuclear cells (PBMCs) were
isolated by Ficoll (GE Healthcare Life Sciences, Uppsala,
Sweden) density gradient, as described previously [15, 37,
39]. Of these PBMCs, ∼13 × 106 cells were subjected to the
short-term lymphocyte stimulation test (LST) to determine the
proliferative capacity of T-cells against the indicated proteins
of HPV16 [15, 39]. Nine milliliters of blood collected into a
clotting tube was used to isolate serum by centrifugation for
7 min at 1800 g, which was used in the LST, as described
previously [15, 39]. The remaining PBMCs were cryopre-
served in 80% Fetal Bovine Serum (FBS, Biowest, EU qual-
ity) and 20% DMSO (Merck, Darmstadt, Germany) and
stored in liquid nitrogen.
HPV16 peptides
Eight peptide pools of HPV16 peptides were used to deter-
mine the proliferative capacity of HPV16-specific T-cells, and
the cytokine polarization and frequency of HPV16-specific
Foxp3+ regulatory T-cells, as described previously [15, 37,
39]. 30 (or 35) amino-acid-long peptides with 14- (or
15-)mer overlap covering the HPV16 E2, E6, and E7 protein
sequences were synthesized by the solid-phase peptide syn-
thesis (SPPS) method with >95% purity (ChinaPeptides Co.,
Shanghai, China). Two pools of E2 peptides (E2.1 and E2.2)
consisted of 12 or 11 (30-mer) peptides, respectively. Four
pools of E6 (E6.1–E6.4) and two pools of E7 peptides (E7.1
and E7.2) consisted of two 32-mer or 35-mer peptides, respec-
tively [15]. Memory response mix (MRM) stock solution
(50×), consisting of tetanus toxoid, 0.75 fL/mL (Statens
Serum Institut, Copenhagen, Denmark), tuberculin purified
protein derivative (PPD), 5 μg/mL (Statens Serum Institut),
and Candida albicans, 0.015% (Greer Laboratories, Lenoir,
NC, USA) was used as a positive control for the proliferation
assays and cytokine production capacity of the PBMCs [15,
39].
Determination of the proliferative capacity of HPV16-specific
T-cells by the short-term LST
LSTwas performed as described previously [15, 39]. Briefly,
PBMCs were cultured in eight replicative wells in the pres-
ence of the indicated peptide pool at a final concentration of
5 μg/mL per peptide. PBMCs cultured with MRM were used
as a positive control and with no antigen (medium only) as a
background control. After culturing for 6 days, supernatant
from the replicative wells was pooled and stored for cytokine
analysis. The proliferation of cells were determined by the
[3H]-thymidine incorporation assay. The cut-off value for
counts per minute (CPM) values was determined by the aver-
age plus 3 × standard deviation (SD) of the eight medium-only
control wells. The stimulation index (SI) was calculated as the
average of the eight tested wells divided by the average of the
medium-only control wells. The proliferative response was
defined as positive if the CPM values of at least six of the
eight wells were above the cut-off value and if the SI was ≥3.
Cytokine polarization analysis
The supernatants from PBMC cultures were analyzed using
the Cytometric Bead Array (CBA) human enhanced sensitiv-
ity flex set system (BD Biosciences, Temse, Belgium), ac-
cording to the manufacturer’s instructions. In this array, the
levels of IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-10, and IL-17A
were determined, as previously described [4, 15, 39]. The
detection limits for the cytokines were based on standard
curves complying with the limit of 274 fg/mL, as described
by the manufacturer. The positive antigen-induced cytokine
production was defined as a cytokine concentration >2× the
concentration of the medium-only control.
Identification of HPV16-specific CD4+CD25+Foxp3+
regulatory T-cells
Regulatory T-cell identification was performed as previously
described [9, 15, 39]. Briefly, PBMCs were cultured with the
same peptide pools as used in the LST at a final concentration
of 5 μg/mL per peptide. Cells cultured with MRM were used
as a positive control and cells without antigen (medium only)
were used as a background control. After 7 days of culturing,
the cells were harvested and stained with surface markers
CD25 (1:25) (anti-CD25 FITC, clone M-A251, BD
Pharmingen, San Diego, CA, USA), CD4 (1:100) (anti-
CD4-APC, clone RPA-T4, BD Pharmingen), CD8 (1:30) (an-
ti-CD8 PerCP-Cy5.5; clone SK1, BD Pharmingen), and intra-
cellular marker Foxp3 (PE anti-human FOXP3, clone 206D,
BioLegend) or isotype control (PE Mouse IgG1, κ Isotype
Ctrl, BioLegend). After staining, the cells were acquired by
the flow cytometer BD FACSCalibur (BD Biosciences).
Analysis was performed by using Flowing Software, version
2.5.0 (Cell Imaging Core, Turku Centre for Biotechnology,
Turku, Finland). The fluorescent intensity of MRM-
stimulated and medium-only control cells was used to set
the gates for the other samples. An antigen-induced alter-
ation in the population percentage was defined as a
change of at least 2× the corresponding percentage in
the medium-only controls.
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Statistical analysis
The means of secreted cytokine concentrations and prolifera-
tive responses of all groups were analyzed using one-way
analysis of variance (ANOVA). The Bonferroni correction
was used to control for multiple comparisons between the
groups. All statistical tests were two-sided and declared sig-
nificant at a p-value ≤0.05. All statistical analyses were run
using the IBM SPSS® (IBM, Inc., New York, USA) software
package (IBM SPSS Statistics for Windows, version
22.0.0.1).
Results
Children’s oral HPV DNA status and HPV serology
All 33 children were actively followed up from birth until the
age of 6 years and passively thereafter, until the collection of
the present samples taken now from the children with a mean
age of 14.7 years (median 14.9 years, range 11.7–16.2 years).
The HPV DNA status of the oral mucosa was determined at
birth, at the age of 3 days, 1, 2, 6, 12, 24, 36, and 72 months,
and, finally, at 14.7 years. HPV serology to genotypes 6, 11,
16, 18, and 45 was determined at the same time points from
the age of 1 to 36 months. Fourteen children stayed constantly
HPV-negative during follow-up and HPV16-negative at final
time point, and were considered as controls, while 19 children,
who had either HPV DNA detected in umbilical cord blood
and/or placenta and/or HPV DNA detected in oral mucosa
either continuously (> 24 months) or HPV16 only at the final
time point, were defined as cases. Tables 1 and 2 show the
detailed individual follow-up data.
Among cases, 16 of 19 children were tested for HPVat the
last follow-up visit, and six of them had oral HPV: HPV11
was detected in one, HPV16 in four, and HPV6/16 coinfection
in one child. Overall, oral HPVof any genotype was detected
in all case children during the follow-up of 14.7 years, except
one (ID201), who was HPV cord blood positive but remained
oral HPV DNA-negative during the entire follow-up. In the
control group, 9 of 14 children were tested at the last follow-
up visit, one having oral HPV11. None of these 14 control
children had any HPV DNA detectable in their oral mucosa at
any study point during the original 72 months of follow-up.
The bivalent HPV vaccination showed no significant effect on
HPV detection at the last visit.
Altogether, HPV antibodies for genotypes 6, 11, and 16
were found in 13 of 19 case children, nine of them having
antibodies during the first 2 months of life, i.e., prior to the
emergence of their own antibody production, indicating the
maternal origin of these HPVantibodies. Among the controls,
HPVantibodies were detected in 11 of 14 children, and six of
them had antibodies during the first 2 months of life.
Interestingly, of the 11 children with persistent HPV infection,
ten had the same HPV type detected already at delivery or
during the first 2 months, implicating that HPV acquired at
very early age may predispose to HPV persistence.
Short-term LST and HPV-specific CD4+CD25+Foxp3+
regulatory T-cell detection
The HPV16-specific proliferative responses and frequencies
of CD4+CD25+Foxp3+ regulatory T-cells (Tregs) after 7-day
stimulation of PBMCs in both groups are shown in Fig. 1.
Children in the case group were divided into five subgroups:
(I) HPV DNA-positive placenta and detectable serum HPV
antibodies during the first 2 months after birth; (II) HPV
DNA-positive placenta without any HPV antibodies during
the first 2 months; (III) HPV DNA-positive cord blood with-
out an HPV DNA-positive placenta; (IV) persisting oral HPV
(>24 months) during the active follow-up of 72 months, with-
out an HPV DNA-positive placenta of cord blood; and (V)
negative for oral HPVat all visits during the 72-month follow-
up and testing oral HPV16-positive at the last visit when blood
was taken for CMI. MRM-induced proliferation of the
PBMCs was observed in all 19 case children, indicating that
the PBMCs were capable of proliferating in response to the
common recall antigens. HPV16-specific proliferative re-
sponse was found in 14 of 19 case children, all showing a
response to either both peptide pools of HPV16 E2 or the
E2.2 pool only. Five of the case children were not responding
to any of the HPV16 peptides. These non-responders include
two children (ID305 and ID306), both with persistent oral
HPV16 without any detectable HPV antibodies. The other
two non-responders, ID101 and ID204, were found to be
HPV-negative at the last time point, but were previously pos-
itive for HPV39 and HPV6, respectively. The fifth non-
responder (ID011) had stayed negative for oral HPVat earlier
visits during the 72-month follow-up, but was HPV6-
seropositive during the first 2 months of life and tested
HPV16-positive at the final visit. The percentage of the
HPV16-specific Tregs was increased when compared to back-
ground frequencies (medium control) in two case groups chil-
dren: ID101 had slightly elevated Treg frequency against the
E6.4 peptide pool and ID303 against the E6.3 peptide pool.
In the control group, the PBMCs of 13 of 14 children
responded by proliferation to MRM. The child without an
MRM response (ID006), however, showed reactivity to the
HPV16 peptides. Altogether, 12 of 14 control children
displayed reactivity to E2, of whom eight had a proliferative
response to both HPV16 E2 peptide pools. Five children
responded to the E6 peptides and two to the E7.2 peptide
pools. Two control children (ID001 and ID010) were negative
in the proliferation test for HPV16. As controls, they did not
show any oral HPV positivity during the follow-up, but were
HPV-seropositive (HPV6 and 16 or HPV6, respectively).
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eur J Clin Microbiol Infect Dis
Increased percentages of Tregs specifically responding to
HPV16 peptides were observed in four control children. In
three children (ID002, ID008, and ID010), these Treg fre-
quencies were relatively high and were induced by several
peptide pools.
On the whole, the proliferative response induced to the
HPV16 E6 and E7 oncoproteins was significantly different be-
tween the cases and controls, with a higher frequency in the
control group than in the case groups (p= 0.047). The responses
to the early antigen E2 were not significantly different between
the groups. Similarly, no differences were found when the re-
sponses were stratified by HPV seropositivity (children with
HPV antibodies detectable at 1 or 2 months and children with
HPVantibodies after 2 months of age).
Cytokine polarization analysis
Supernatants of the proliferation tests were collected at day 6
and subjected to a cytometric bead array to analyze the cyto-
kines produced. The selected cytokines IFN-γ, TNF-α, IL-2,
IL-4, IL-5, IL-10, and IL-17A were measured to canvass the
cytokine profile and to assess the presence of IL-17-producing
HPV16-specific CD4+ T-cells. Generally, the levels of all cy-
tokines measured were low (in most cases <100 pg/mL), but
the range was wide (0.27–230.0 pg/mL, mean 6.3 pg/mL).
The cytokine secretion was higher in the cultures displaying
cell proliferation after stimulation than in the other cultures.
IFN-γ, IL-10, and IL-2 were the most frequently detected
cytokines in all children, followed by IL-17A, IL-5, and
TNF-α. The concentrations of IFN-γ and IL-5 were slightly
higher than that of other cytokines. Similar to our previous
study, IL-4 was not detectable except in one case child
(ID303) as a response to the E6.2 peptide pool.
Similar to the proliferation data, the cytokine concentra-
tions were compared between the five case subgroups and
the control group. No differences between the groups were
found when the cytokine secretion by the proliferative
PBMC cultures was analyzed. However, when we considered
the data of all peptide-stimulated PBMC cultures, there was a
significantly higher HPV16 E2-induced production of IL-5
(p = 0.043), IL-10 (p = 0.013), and IL-17A (p = 0.043) in
groups I–III (children with HPV DNA in placenta and/or cord
blood) than in other case subgroups. Furthermore, when the
children who tested HPV-positive in the placenta and/or cord
blood (groups I–III) were stratified by their oral HPV persis-
tence, those with no persistence showed higher TNF-α (p =
0.013), IL-2 (p = 0.009), and IL-5 (p = 0.006) secretion after
E2.1 stimulation (pooled data). Figure 2 shows the mean con-
centrations of each cytokine and illustrates the distinct cyto-
kine pattern in each group. The children born to HPV DNA-
positive placenta and/or HPV-positive cord blood appear to
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IL-10 and IL-17A compared to other subgroups and the con-
trol group.
Overall evaluation of the results singled out two children who
might be considered as having the characteristics of an HPV-
tolerant individual. Child ID305 had had persistent oral
HPV16 at two time points during the follow-up and tested
HPV16-positive also at the last visit with HPV6 coinfection.
Importantly, this child had no detectable HPVantibodies during
the follow-up and, further, had no response to any of the HPV16
peptides. The mother of this child was negative for oral and
genital HPV during the follow-up, including the final time point.
Child ID306 had had oral HPV16 detected at two time
points (24 and 36months) also without any HPV16 antibodies
and no response against HPV16 peptides. No HPV DNAwas
detected in the oral sample at the final visit, which, however,
does not entirely exclude the presence of oral HPV. The moth-
er of this child had genital and oral HPV16 detected once (at
24 months) and persistent genital HPV45, but no HPV anti-
bodies at any time point. Both children were born by vaginal
delivery and the breast milk tested HPV DNA-negative after
delivery. Clinical examination revealed normal oral mucosa at
the 72 months visit.
Discussion
In this study, we examined the HPV16 E2-, E6-, and E7-
specific immune responses in children having distinct HPV
Fig. 1 Results from lymphocyte stimulation test (LST), cytokine
polarization, and Foxp3 assay. a Results of the HPV16-specific LST.
Only positive responses are marked with gray boxes and the stimulation
index is shown below each peptide pool. Memory response mix (MRM)
was used as a positive control. b Supernatants from the LST were
analyzed for the presence of cytokines IFN-γ, TNF-α, IL-2, IL-5, IL-
10, and IL-17A. Each small gray square represents the production of
one of the six cytokines as the layout indicates. c The increased
frequencies of CD4+CD25+Foxp3+ Tregs are shown. Upregulation of
Tregs is defined as at least twice the percentages of Tregs in the medium-
only control
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profiles during the first 6 years of their lives. We found CMI
responsiveness for E2 peptides in the majority of all tested
children (78.8% of 33 children). This responsiveness was sim-
ilar regardless of the child’s HPV status during the follow-up.
The CMI responses against HPV16 E6 and E7 peptides were
detected in 24.2% of children and were significantly more
frequent in children who stayed constantly negative for oral
HPV than in children with oral, placental, or cord blood HPV
DNA. Interestingly, the analysis of the secretion patterns of
Th1 and Th2 cytokines as a response to HPV16 peptides in-
dicated more pronounced Th2 response in children born with
HPV DNA-positive placenta and/or HPV-positive cord blood.
Our previous studies [13, 15] were the first to demonstrate
that HPV16-specific immune responses exist among unvacci-
nated and sexually inexperienced children aged between 10
and 14 years. We found that 93.5% (29/31) of such children
carried blood lymphocytes responsive to peptides overlapping
the amino acid sequences of HPV16 E2 and E6 proteins.
Unexpectedly, the HPV-related disease (CIN1–3) of the moth-
er did not show any significant impact on the HPV16-specific
immune responses of her child, when children born to HPV-
negative mothers were used as the reference [15]. These re-
sults prompted us to further evaluate the possible effect of very
early or long-term exposure to HPV on the appearance of
HPV-specific CMI responses compared to children without
HPV infection.
The cytokine polarization of HPV16 E2-, E6-, and E7-
stimulated PBMCs was determined to canvass the possible
alterations between types 1 and 2 cytokines. As the defects
in the immune response against HPV have been linkedwith an
increase in type 2 cytokines [3], it was reasoned that a com-
parison of the cytokine secretion patterns in children exposed
to HPV in the early stages of their lives with HPV-negative
children might reveal some differences. Since our previous
observations implicating the important role of the placenta in
the transmission of HPV [14, 25], the children with HPV
DNA detected in placenta and/or cord blood were of special
interest. Indeed, we found significantly higher HPV16 E2-
induced levels of IL-5, IL-10, and IL-17A in placenta/cord
blood HPV-positive children than in other case subgroups,
indicating a more dominant Th2 effector or regulatory re-
sponse, and further raising questions about the conceivable
effects of HPVexposure during the prenatal period.
Earlier studies in mice have shown that inoculation of new-
born mice with high doses of murine retrovirus induces type 2
cytokine responses, while low viral doses induce type 1 re-
sponses. Further, the initial viral dose with relation to the
number of potentially responsive T-cells is critical for the in-
duction of Th1 and Th2 responses and development of pro-
tective immunity in newborn mice. Thus, the lower T-cell
number in neonates compared to adults explains the reduced
immune responses to same antigen [6, 21, 26].
However, normal pregnancy in humans is known to be
associated with Th2 skewing and the Th2 cytokine-
dominated milieu at the placenta was suggested to establish
a kind of protective homeostasis [27]. This Th2 predominance
persists in the newborn’s system after birth for at least several
months before the realignment of the Th1/Th2 environment
[1, 5]. Thus, the continuation of this Th2 skewing or delaying
of Th1 maturation is associated with atopy and other allergic
diseases [1]. According to our results, one could hypothesize
that HPV infection or exposure to viral antigens during the
prenatal period might affect the activation and type of immune
responses during later encounters with HPVand, further, even
the outcome of the infection, which would, however, need a
longer follow-up in order to be solved.
As in our previous observations, HPV16 E2 peptides were,
once again, the most antigenic epitopes, inducing proliferative
response similarly among the cases and the controls. The pro-
liferative response to HPV16 E6 peptides was also found
Fig. 2 The mean fraction of each cytokine from the total amount of cytokine secretion among each subgroup. The fractions for each cytokine produced
by each individual against all tested peptide pools were determined, and the mean of those fractions of whole subgroup were calculated
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frequently. The responsiveness of control children to E2 and
E6 peptides is in line with the previous observations in healthy
adults [3, 4, 11, 38], while the proliferative responses of case
children resemble more the pattern of mothers with CIN1–3 in
our previous study [15]. Since HPV-specific immunity in chil-
dren has not been reported in any other studies apart from our
previous works, any comparisons of the current results are
precluded.
Because HPV E2 is the main factor in the transcription
initiation and regulation of viral genes and, therefore, abun-
dant in all HPV-infected cells at the stage of viral amplifica-
tion, the individual’s responsiveness to HPV16 E2 peptides
alludes to the existence of circulating HPV16 E2-specific
memory T-cells, originating from prior or present replicative
HPV16 infection [17]. Furthermore, a cross-reactivity of
HPV16 E2, E6, and E7 peptides with T-cells specific to other
closely related HPV types is conceivable, albeit a rarely ob-
served event [3, 4, 33, 40].
Interestingly, we could identify two case children (ID305
and ID306) with persistent oral HPV16 (HPV DNA detected
in repeated samples over 24months) who showed no response
to any HPV16 peptides. In general, the measured cytokine
production was below the cut-off values as expected, since
no HPV16-specific T-cell proliferation was detected in these
children. Both of them had demonstrated oral HPV16 persis-
tence during their active follow-up without HPV16 antibod-
ies, and ID305 had oral HPV16 DNA detected also at the last
(15 years) visit. This child had also received three doses of
bivalent HPV vaccination, while child ID306 was not vacci-
nated. At the moment, we cannot ascertain whether the repeat-
edly detected DNA of a given HPV type in the oral mucosa is
a sign of persistent HPV infection or if it is a new encounter
with the same HPV type. However, our recent (unpublished)
data on persistent oral HPV16 infections in adults have shown
that HPV16 is either in an integrated or mixed physical state,
confirming the concept of HPV persistence. In the same study,
all subjects who cleared their oral infection had HPV16 in an
episomal state (Lorenzo et al., unpublished). It is tempting to
consider that children who received prophylactic HPV vacci-
nation and who show persistent oral HPV16 infection might
have an integrated HPV16, undetectable by the antibodies
elicited by the HPV vaccination. In addition, it might well
be that these two children, especially ID305, carrying persis-
tent oral HPV16 without any detectable immunological re-
sponses, can have a specific defect in their immune system
or even conceivable features of HPV tolerance. We also no-
ticed that, in children with persistent HPV during the follow-
up, the same HPV type was detected already at birth or during
the first 2 months of life, implying that these very early infec-
tions could be more prone to remaining persistent. In addition,
another child (ID011) in the case group showed no HPV16-
specific response, but still had HPV16 DNA detectable in the
oral mucosa. In this case, one possible explanation for the lack
of immune response could be a very recent infection, not yet
recognized by the adaptive immune system [29]. This partic-
ular child had not been vaccinated against HPV before CMI
testing. The remaining four children without HPV16-specific
CMI had no oral HPV16 detected during the follow-up.
To conclude, these results support our earlier observations
on the existence of HPV16-specific CMI in children [13, 15].
It seems that the vast majority of children carry CD4+ mem-
ory T-cells responsive to peptides of HPV16. Accordingly,
these observations suggest that all these children had been
exposed to HPV16 during their early lives, regardless of their
oral HPV status at each time point during follow-up.
However, a substantial proportion of children who remained
oral HPV-negative during follow-up showed also response
against the HPV16 E6 protein, suggesting an importance of
HPV16 E2- and E6-induced CMI in the successful control of
HPV infection. In turn, the unresponsiveness to HPV16 pep-
tides seen in some children with persistent oral HPV16 might
suggest a kind of specific defect in their immune system. The
more dominant Th2 cytokine profile in cases who were infect-
ed early during life insinuates that either the viral dose or the
specific Th2 microenvironment installed by the placenta may
have a significant role in steering the type of HPV-specific
immunity in young children.
Altogether, the present findings of HPV16-specific CMI,
together with our earlier data on the natural history of HPV
infections during infancy and childhood, attest the view that
an early exposure to HPV might be highly relevant for the
subsequent HPV infections in adulthood, and also have some
influence on the effectiveness of prophylactic HPV vaccines.
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